Canaccord Genuity Analysts Give Voyager Therapeutics (VYGR) a $35.00 Price Target

Canaccord Genuity set a $35.00 target price on Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Monday. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently issued reports on VYGR. BidaskClub raised shares of Voyager Therapeutics from a hold rating to a buy rating in a research note on Saturday, February 24th. BTIG Research reissued a buy rating and issued a $32.00 price target on shares of Voyager Therapeutics in a research note on Sunday, March 11th. Piper Jaffray reissued a buy rating and issued a $40.00 price target on shares of Voyager Therapeutics in a research note on Monday, March 12th. Wedbush cut shares of Voyager Therapeutics from an outperform rating to a neutral rating and set a $29.00 price target on the stock. in a research note on Monday, March 12th. Finally, Morgan Stanley lifted their price target on shares of Voyager Therapeutics from $36.00 to $39.00 and gave the company an overweight rating in a research note on Wednesday, February 21st. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $29.73.

Voyager Therapeutics stock opened at $19.66 on Monday. Voyager Therapeutics has a 1 year low of $8.10 and a 1 year high of $31.91. The firm has a market capitalization of $619.34, a P/E ratio of -7.45 and a beta of 2.97.



Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Wednesday, March 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.32. Voyager Therapeutics had a negative net margin of 697.03% and a negative return on equity of 63.18%. The firm had revenue of $6.35 million for the quarter, compared to analysts’ expectations of $5.81 million. equities analysts expect that Voyager Therapeutics will post -2.54 earnings per share for the current fiscal year.

In other Voyager Therapeutics news, insider Bernard Ravina sold 2,451 shares of Voyager Therapeutics stock in a transaction on Monday, February 12th. The shares were sold at an average price of $18.24, for a total transaction of $44,706.24. Following the sale, the insider now owns 4,902 shares of the company’s stock, valued at approximately $89,412.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dinah Ph.D. Sah sold 15,623 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total transaction of $468,690.00. Following the sale, the insider now directly owns 140,872 shares in the company, valued at approximately $4,226,160. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 66,908 shares of company stock worth $1,574,258. 8.00% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Thompson Davis & CO. Inc. boosted its stake in Voyager Therapeutics by 67.7% during the 4th quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock worth $124,000 after purchasing an additional 3,021 shares during the last quarter. MetLife Investment Advisors LLC acquired a new stake in Voyager Therapeutics during the 4th quarter worth $128,000. California State Teachers Retirement System boosted its stake in Voyager Therapeutics by 8.4% during the 2nd quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock worth $231,000 after purchasing an additional 2,000 shares during the last quarter. Bailard Inc. acquired a new stake in Voyager Therapeutics during the 4th quarter worth $232,000. Finally, JPMorgan Chase & Co. acquired a new stake in Voyager Therapeutics during the 3rd quarter worth $270,000. 78.22% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://dakotafinancialnews.com/2018/04/13/canaccord-genuity-analysts-give-voyager-therapeutics-vygr-a-35-00-price-target.html.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply